NAMS · NewAmsterdam Pharma Company NV
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Market Cap
2.208B
52 Wk Range
$17.90 - $42.20
Previous Close
$19.51
Open
$19.21
Volume
1,745,134
Day Range
$18.28 - $19.78
Enterprise Value
1.58B
Cash
628.2M
Avg Qtr Burn
-39.77M
Insider Ownership
0.89%
Institutional Own.
N/A
Qtr Updated
Sep 30th 2026
